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ulators — regardless of what 
decision was made regarding con-
tinued development of the mole-
cule — would increase the safety 
of future studies. If this system 
were designed not to be so intru-
sive as to inhibit innovation but 
nonetheless to provide sufficient 
transparency, it would help to 
ensure that safety lessons need 
not be relearned repeatedly. In-
deed, it is difficult to imagine how 
regulators can currently approve 
phase 1 studies without access to 
such data in a readily searchable 
format during the review process.
The details of this trial, in-
cluding such crucial facts as the 
dose, rate of drug administra-
tion, planned number of doses, 
intervals between doses, and even 
whether multiple doses were re-
ceived by any volunteer, were ini-
tially kept confidential under cur-
rent laws in the United Kingdom. 
The MHRA has now decided to 
release the details of the trial, in-
cluding its protocol,1 which makes 
clear that the intent was to study 
four groups of eight volunteers 
with each group receiving pro-
gressively higher doses; two vol-
unteers in each group were to 
receive placebo. Only the first 
group was studied. However, this 
incident once again raises the 
question of whether such trials 
should be registered in an acces-
sible database such as Clinical-
Trials.gov.5 There are fundamen-
tal questions about which, if any, 
details of a clinical trial involv-
ing volunteers should ever be con-
fidential or whether safety and 
ethics principles can be ensured 
only by an open, transparent pro-
cess in which such trials and pro-
tocols are registered in a public 
database. This issue has become 
more urgent in the light of both 
this recent incident and the mi-
gration of clinical trials to less 
developed countries, where over-
sight may be less rigorous.
Although it is important to em-
phasize that most phase 1 stud-
ies have been safe, it is equally 
important to ensure that lessons 
are learned from this experience 
and systems put in place to mini-
mize the risk of recurrence. We 
must not squander the experience 
of the participants in such trials 
by failing to share the knowledge 
gained with their help. We have 
an opportunity to learn from events 
in the TeGenero study how to im-
prove early drug evaluation, and 
we clearly need to do so as we de-
velop more and more new com-
pounds. Academia, the pharmaceu-
tical and biotechnology industries, 
and regulators must work togeth-
er to prevent such clinical-research 
nightmares from happening in 
the future.
An interview with Dr. Wood can be heard at 
www.nejm.org. 
Dr. Wood is a professor of medicine and phar-
macology at Vanderbilt University School of 
Medicine, Nashville. Dr. Darbyshire is the di-
rector of the Clinical Trials Unit of the Medi-
cal Research Council, London.
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injury to research volunteers — the clinical-research nightmare
Compensation for Injured Research Subjects
Robert Steinbrook, M.D.
T wo recent developments — increased awareness of the 
complications that may follow egg 
donation for stem-cell research 
and the disastrous consequences 
of a clinical trial of the humanized 
monoclonal antibody TGN1412 in 
which healthy volunteers nearly 
died (discussed above by Wood and 
Darbyshire) — have focused re-
newed attention on the long-stand-
ing issue of compensation for in-
jured research subjects.1 In the 
United States, despite decades of 
discussion and recommendations 
by national commissions, spon-
sors and institutions are not re-
quired to provide either free med-
ical care or compensation, although 
some do. In contrast, many Euro-
pean countries mandate the pro-
vision of clinical-trials insurance, 
through which subjects are often 
covered regardless of fault.
Participation in clinical trials 
always carries some risk, but seri-
ous injury or death is rare, partic-
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ularly for healthy volunteers. There 
is, however, little systematic in-
formation about the severity, fre-
quency, and types of injuries or 
about their costs.2 Injuries may 
result from the research procedure, 
as in the case of a spinal headache 
after a lumbar puncture, an ankle 
injury from falling off a treadmill, 
or the ovarian hyperstimulation 
syndrome after egg donation. In-
juries may also result from the 
medication or device being tested 
or from an investigator’s failure 
to follow the protocol or to per-
form the procedures correctly.
One view is that sponsors and 
institutions are obligated to com-
pensate injured subjects, partic-
ularly in trials with commercial 
sponsors and regardless of who 
may be to blame or whether the 
participants were paid.2,3 The con-
trary view is that routine com-
pensation is not required because 
subjects are made aware of the 
risks through the informed-con-
sent process, understand them, 
and voluntarily agree to partici-
pate. There are also practical is-
sues. For instance, it may be dif-
ficult to determine whether a 
medical problem is related to par-
ticipation in a clinical trial, par-
ticularly if it develops months or 
years later or if a subject has other 
risk factors. The costs of provid-
ing compensation include the 
need to adjudicate claims and re-
solve disagreements. Plans with 
broad coverage are more costly 
and difficult to administer than 
those that are limited to cover-
ing direct medical costs.
As part of the informed-consent 
process for research “involving 
more than minimal risk,” regula-
tions of the Department of Health 
and Human Services require that 
potential subjects be told wheth-
er any compensation or medical 
treatments “are available if inju-
ry occurs and, if so, what they 
consist of, and where further in-
formation may be obtained.” A 
recent study commissioned by the 
department found that most re-
search institutions do not have 
policies that provide free care or 
compensation to injured partici-
pants (see table).4 The authors of 
the study reviewed 129 policies at 
102 academic medical centers and 
found that there was “no institu-
tion or sponsor offering to com-
pensate for lost wages or pain 
and suffering,” that only 21 poli-
cies (16.3 percent) “involved pro-
viding free care or treatment,” and 
that health insurance “serves as 
the primary vehicle for compen-
sation of such injuries in the Unit-
ed States.” 4 The extent of cover-
age for research injuries may vary 
among health insurance policies.
The University of Washington 
is one institution with a long-
standing compensation plan. The 
university’s self-insured, no-fault 
plan dates from the 1970s. It cov-
ers medical expenses associated 
with adverse events and some in-
cidental expenses, such as travel 
and child care. The division of fi-
nancial responsibility between 
commercial sponsors and the uni-
versity is specified in negotiated 
agreements. The university typi-
cally has one or two claims per 
year, and it writes off the cost of 
in-house medical expenses.
Institutional policies may not, 
compensation for injured research subjects
Characteristics of 129 Policies for Injuries to Research Volunteers at 102 Academic 
Medical Centers in the United States.*
Policy Provision Policies
no. (%)
Free care not provided 66 (51.2)
Medical treatment billed at usual and customary fees 54
Emergency or immediate treatment billed at usual 
and customary fees
12
Free care provided 21 (16.3)
Medical treatment 10
Emergency or immediate care 11
Care billed to insurance first but free for those without insurance 13 (10.1)
Medical treatment 9
Emergency or immediate care 4
Care billed on a case-by-case basis 5 (3.9)
No publicly accessible information 24 (18.6)
* Data are from a survey conducted by the Lewin Group4 and are primarily based 
on a review of sample informed-consent forms and other information from the 
Web sites of 126 major medical centers. Usable information was obtained from 
102 institutions. The number of policies is greater than the number of institutions 
because some institutions had different policies for different circumstances, such 
as whether the research had a private sponsor.
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of course, reflect what actually 
happens after an injury occurs or 
the role of litigation in helping 
subjects obtain compensation.5 
Commercial sponsors may have 
their own policies regarding pay-
ments for treatment of injuries 
or contracts with institutions spec-
ifying who is responsible in var-
ious situations. Some institutions 
may require insurance arrange-
ments. Some may absorb the costs 
of care for subjects who do not 
have health insurance or who have 
large copayments or deductibles. 
Some federal agencies — such 
as the Department of Veterans 
Affairs, the Department of De-
fense, and the National Institutes 
of Health Clinical Center — have 
requirements for the provision 
of short-term medical care to re-
search subjects. The federal Medi-
care program will pay for care, 
including care for medical com-
plications, for beneficiaries who 
take part in qualifying clinical 
trials. 
The United States lacks nation-
al standards for either no-fault 
procedures or compensation guide-
lines for research-related injuries. 
The National Vaccine Injury Com-
pensation Program, which has 
been in effect since 1988, is often 
cited as the closest example of 
such a standard.4 The program is 
a no-fault alternative to the tradi-
tional tort system for resolving 
vaccine injury claims. It covers all 
vaccines recommended by the Cen-
ters for Disease Control and Pre-
vention for routine administration 
to children.
The situation in Europe is much 
different, in part because many 
countries have universal health 
insurance. The 2001 European di-
rective on the conduct of clinical 
trials states that a trial may be 
undertaken only if “provision has 
been made for insurance or in-
demnity to cover the liability of 
the investigator and sponsor.” 
Some countries — such as France, 
Germany, and Spain — have com-
pulsory insurance laws, although 
there is variation in the specif-
ics and in the minimum cover-
age that is required.2,4 Whereas 
clinical-trials insurance is not 
required in the United Kingdom, 
where the TGN1412 trial was 
conducted, government guidance 
for researchers — as well as the 
guidelines of the Association of 
the British Pharmaceutical In-
dustry — states that compensa-
tion should be provided. Although 
such compensation may be ade-
quate in many situations, it may 
be insufficient to cover extraor-
dinary injuries, such as those in 
the TGN1412 trial.
In 2002, the Institute of Med-
icine issued the recommendation 
that “organizations conducting 
research should compensate any 
research participant who is in-
jured as a direct result of partici-
pating in research, without re-
gard to fault. Compensation should 
include at least the costs of med-
ical care and rehabilitation, and 
accrediting bodies should include 
such compensation as a require-
ment of accreditation.”2 Though 
little appears to have changed, 
there has been progress in the 
area of egg donation. In Febru-
ary 2006, the California Institute 
for Regenerative Medicine pro-
posed regulations that would re-
quire institutions to which it pro-
vides funding for deriving human 
stem-cell lines “to assume the 
cost of any medical care required 
as a direct and proximate result 
of oocyte donation for research.” 
The institute has prohibited pay-
ment for a donor’s time or eggs.
Although the ethical arguments 
for compensating injured research 
subjects are compelling, the prac-
tical details are complicated — 
particularly the determination of 
the extent and duration of cover-
age and the assignment of the 
responsibility for paying com-
pensation. However, the actuarial 
expense of covering direct medi-
cal costs may be relatively low, 
because serious injuries are un-
usual. In the United States, nation-
al leadership — from the clinical-
trials industry, academic medical 
centers, and the federal govern-
ment — will be needed to cata-
lyze major change.
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